Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open



    OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in
   Previously Treated Metastatic Bladder Cancer is now Open for Enrollment

The OGX-427 ORCA™ Program Continues to Expand with Patient Enrollment Now Open
for Second Phase 2 Trial of OGX-427 in Advanced Bladder Cancer

PR Newswire

BOTHELL, Wash. and VANCOUVER, British Columbia, April 30, 2013

BOTHELL, Wash. and VANCOUVER, British Columbia, April 30, 2013 /PRNewswire/ --
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of
the Borealis-2™ clinical trial, an investigator-sponsored, randomized Phase 2
trial evaluating OGX-427 in combination with docetaxel in patients with
advanced or metastatic bladder cancer who have disease progression following
first-line platinum-based chemotherapy treatment.

Borealis-2 will randomize approximately 200 patients to receive either OGX-427
plus docetaxel treatment or docetaxel treatment alone. Patients may also
continue weekly OGX-427 infusions as maintenance treatment until disease
progression or unacceptable toxicity if they complete all 10 planned cycles of
docetaxel or are discontinued from docetaxel due to docetaxel toxicity. The
primary endpoint of the trial is overall survival, with secondary objectives
to evaluate safety, tolerability, tumor response rates and the effect of
therapy on heat shock protein (Hsp27) levels and circulating tumor cells.

"Resistance to initial chemotherapy is a frequent occurrence in patients with
advanced bladder cancer, and is often frustrating for physicians and
devastating for patients who have limited treatment options available," stated
Noah M. Hahn MD, Associate Professor of Medicine at Indiana University Simon
Cancer Center and one of the primary investigators on the trial. "We hope that
this trial will shed new light on the role of Hsp27 in bladder cancer and the
ability of OGX-427 to work synergistically with second- or third-line
chemotherapy to overcome resistance and prolong survival."

Borealis-2 is the second randomized, controlled clinical trial of OGX-427 in
advanced bladder cancer.  Borealis-1™ is a company-sponsored, randomized,
placebo-controlled Phase 2 trial of OGX-427 in combination with first-line
gemcitabine and cisplatin in patients with metastatic bladder cancer. If
either Borealis trial shows a survival advantage, OncoGenex plans to initiate
conversations with the Food and Drug Administration about the possibility of a
Phase 3 trial of OGX-427 in bladder cancer as part of the ORCA™ program. 

Borealis-2 is being conducted at approximately 30 sites in the U.S. and is
sponsored by the Hoosier Oncology Group. Dr. Noah Hahn from the Indiana
University Simon Cancer Center, Dr. Toni Choueiri from the Dana-Farber Cancer
Institute and Dr. Jonathan Rosenberg from Memorial Sloan-Kettering Cancer
Center will serve as the primary investigators on the trial. Please visit
http://clinicaltrials.gov/show/NCT01780545 for more information.

ABOUT BLADDER CANCER
Nearly 400,000 cases of bladder cancer are diagnosed per year, worldwide.
Approximately 30 percent of patients have locally invasive or metastatic
disease at the time of diagnosis, and 50 percent of patients with locally
invasive disease relapse with metastases within two years. Limited options
exist for both the first- and second-line treatment of advanced bladder
cancer. First-line platinum-based chemotherapy regimens result in a median
overall survival of approximately 12-15 months. Docetaxel is commonly used in
second-line treatment, with a reported median overall survival of
approximately six months. Given acquired treatment resistance and these short
survival times, there continues to be a high unmet need for additional
therapeutic options for this patient population.

ABOUT OGX-427 and ORCA™
OGX-427 is a once-weekly intravenous (IV) drug that is designed to inhibit
production of heat shock protein (Hsp27) to disable cancer cells' defenses and
overcome treatment resistance. Hsp27 is an intracellular protein that protects
cancer cells by helping them survive, leading to resistance and more
aggressive cancer phenotypes.

The ORCA (Ongoing Studies Evaluating Treatment Resistance in CAncer) program
encompasses clinical trials of OGX-427. Phase 2 clinical trials are underway
in bladder, lung and prostate cancers, with additional trials expected to
initiate this year. For more information on OGX-427 and ORCA, please visit
www.OncoGenex.com.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical
Industries Ltd. (NYSE: TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in
Phase 2 clinical development and OGX-225 is currently in pre-clinical
development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements concerning our anticipated
product development activities, such as expected clinical trial completion and
design and statements regarding the potential benefits and potential
development of our product candidates. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current expectations
and beliefs and are subject to a number of risks, uncertainties and
assumptions that could cause actual results to differ materially from those
described in the forward-looking statements, including, among others, the risk
that our product candidates will not demonstrate the hypothesized or expected
benefits, the risk of delays in our expected clinical trials, the risk that
new developments in the rapidly evolving cancer therapy landscape require
changes in our clinical trial plans or limit the potential benefits of our
product candidates and the other factors described in our risk factors set
forth in our filings with the Securities and Exchange Commission from time to
time, including the Company's Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q. The Company undertakes no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof, other than as may be required
by applicable law.

Borealis-1™, Borealis-2™ and ORCA™ are registered trademarks of OncoGenex
Pharmaceuticals, Inc.

SOURCE OncoGenex Pharmaceuticals, Inc.

Website: http://www.oncogenex.com
Contact: Media Contact: Jaime Welch, jwelch@oncogenex.com, 604-630-5403, or
Investor Relations Contact: Susan Specht, sspecht@oncogenex.com, 425-686-1535
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement